REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $63K invested in REGENERX BIOPHARMACEUTICALS in 2017 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
54% more capital invested
Capital invested by funds: $41K → $63K (+$22K)
0% more funds holding
Funds holding: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WJA
Williams Jones & Associates
New York
|
+$13.3K |
Top Sellers
RGN Hedge Fund Activity: Q3 2017 in Review
2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q3 2017, worth a combined $63K — up 54% from $41K a quarter earlier.
Fund positioning in RGN was balanced in Q3 2017: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Williams Jones & Associates, adding an estimated $13.3K.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $63K of REGENERX BIOPHARMACEUTICALS stock for Q3 2017, up 54% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q3 2017 and 0 closed out.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q3 2017 was Williams Jones & Associates, an estimated $13.3K added.
Based on aggregated 13F filings for Q3 2017.